Wells Fargo
CNTB

Wells Fargo’s Connect Biopharma Holdings CNTB Stock Holding History

Wells Fargo’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$1K – 6732
2022
Q2 		$1K Buy
1,000
+997
+33,233% +$1.47K ﹤0.01% 6483
2022
Q1 		$0 Buy
+3
New +$13 ﹤0.01% 7137

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's CNTB Position: Q3 2022 in Review

Wells Fargo sold out of Connect Biopharma Holdings (CNTB) in Q3 2022, closing a stake of 1,000 shares — an estimated $1K sold.

Wells Fargo first reported a position in CNTB in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 25 funds tracked by Wall St. Rank hold CNTB as of Q3 2022.

  • Wells Fargo reported no remaining Connect Biopharma Holdings position as of Q3 2022 after selling out during the quarter.
  • Wells Fargo sold 1,000 Connect Biopharma Holdings shares in Q3 2022, an estimated $1K.
  • Wells Fargo first reported a position in Connect Biopharma Holdings in Q1 2022 and held it in 2 quarters.
  • Wells Fargo's Connect Biopharma Holdings position peaked at $1K in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q3 2022.

Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.